Grace Therapeutics (GRCE) Cash From Investing

Annual CFI

$104.00 K
-$13.05 M-99.21%

March 1, 2024

Summary

Performance

1-Year Change

-99.21%

3-Year Change

+101.05%

5-Year Change

+101.1%

15-Year Change

-97.99%

GRCE Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

68.59%
GRCE annual cash flow from investing activities is higher than 68.59% of companies in Healthcare sector

High & Low

All-time High

$13.15 M
GRCE annual cash flow from investing activities is currently -99.21% below its historical high of $13.15 million

3-Year Low

-$9.86 M

Earnings dates

Last Annual Earnings Report Date

Mar 1, 2024
GRCE previous annual earnings announcement was published on Mar 1, 2024

Next Annual Earnings Report Date

Feb 12, 2025
GRCE next annual earnings announcement is scheduled for Feb 12, 2025

OtherGRCEcash flowmetrics:

Annual CFF

$7.36 M
GRCE annual cash flow from financing activities is $7.36 million

Annual CFO

-$12.33 M
GRCE annual cash flow from operations is -$12.33 million

Annual FCF

-$12.36 M
GRCE annual free cash flow is -$12.36 million

Annual CAPEX

-
GRCE annual capital expenditures value is unknown

Quarterly CFI

$0.00
+$15.00 K+100.00%

September 1, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+100%

3-Year Change

+100%

5-Year Change

-100%

GRCE Quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

68.21%
GRCE quarterly cash flow from investing activities is higher than 68.21% of companies in Healthcare sector

High & Low

All-time High

$13.26 M
GRCE quarterly cash flow from investing activities is currently -100.00% below its historical high of $13.26 million

3-Year Low

-$6.55 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
GRCE previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

Feb 12, 2025
GRCE next earnings announcement is scheduled for Feb 12, 2025

OtherGRCEcash flowmetrics:

Quarterly CFF

$0.00
GRCE quarterly cash flow from financing activities is $0.00

Quarterly CFO

-$4.24 M
GRCE quarterly cash flow from operations is -$4.24 million

Quarterly FCF

-$4.24 M
GRCE quarterly free cash flow is -$4.24 million

Quarterly CAPEX

-
GRCE quarterly capital expenditures value is unknown

TTM CFI

-$21.00 K
-$110.00 K-123.60%

September 1, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+98.55%

3-Year Change

-100.15%

5-Year Change

+99.87%

GRCE TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

60.85%
GRCE TTM cash flow from investing activities is higher than 60.85% of companies in Healthcare sector

High & Low

All-time High

$16.66 M
GRCE TTM cash flow from investing activities is currently -100.13% below its historical high of $16.66 million

3-Year Low

-$11.95 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
GRCE previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

Feb 12, 2025
GRCE next earnings announcement is scheduled for Feb 12, 2025

OtherGRCEcash flowmetrics:

TTM CFF

$0.00
GRCE TTM cash flow from financing activities is $0.00

TTM CFO

-$11.81 M
GRCE TTM cash flow from operations is -$11.81 million

TTM FCF

-$11.81 M
GRCE TTM free cash flow is -$11.81 million

TTM CAPEX

-
GRCE TTM capital expenditures value is unknown

Cash From Investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

GRCE Cash From Investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-99.2%+100.0%+98.5%
3 y3 years+101.0%+100.0%-100.2%
5 y5 years+101.1%-100.0%+99.9%

GRCE Cash From Investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-99.2%+101.0%-100.0%+100.0%-100.1%+99.8%
5 y5-year-99.2%+101.0%-100.0%+100.0%-100.1%+99.9%
alltimeall time-99.2%+100.6%-100.0%+100.0%-100.1%+99.9%

Grace Therapeutics Cash From Investing History

DateAnnualQuarterlyTTM
Sep 2024
-
$0.00(-100.0%)
-$21.00 K(-123.6%)
Jun 2024
-
-$15.00 K(-100.2%)
$89.00 K(-14.4%)
Mar 2024
$104.00 K(-99.2%)
$6.55 M(-199.9%)
$104.00 K(-107.2%)
Dec 2023
-
-$6.55 M(-6058.2%)
-$1.45 M(-1537.6%)
Sep 2023
-
$110.00 K(>+9900.0%)
$101.00 K(-196.2%)
Jun 2023
-
$0.00(-100.0%)
-$105.00 K(-100.8%)
Mar 2023
$13.15 M(-473.5%)
$4.99 M(-199.8%)
$13.15 M(+61.0%)
Dec 2022
-
-$5.00 M(+5109.4%)
$8.17 M(-40.5%)
Sep 2022
-
-$96.00 K(-100.7%)
$13.73 M(-17.6%)
Jun 2022
-
$13.26 M(>+9900.0%)
$16.66 M(-573.1%)
Mar 2022
-$3.52 M(-64.3%)
$11.00 K(-98.0%)
-$3.52 M(-70.5%)
Dec 2021
-
$557.00 K(-80.4%)
-$11.95 M(-13.9%)
Sep 2021
-
$2.84 M(-141.0%)
-$13.88 M(-17.1%)
Jun 2021
-
-$6.93 M(-17.7%)
-$16.75 M(+69.9%)
Mar 2021
-$9.86 M(-221.1%)
-$8.42 M(+513.5%)
-$9.86 M(+435.8%)
Dec 2020
-
-$1.37 M(+4057.6%)
-$1.84 M(+125.8%)
Sep 2020
-
-$33.00 K(-8.3%)
-$815.00 K(-131.5%)
Jun 2020
-
-$36.00 K(-91.0%)
$2.58 M(-68.2%)
Mar 2020
$8.14 M(-186.2%)
-$399.00 K(+15.0%)
$8.14 M(-30.9%)
Dec 2019
-
-$347.00 K(-110.3%)
$11.78 M(-6025.0%)
Sep 2019
-
$3.37 M(-39.0%)
-$198.90 K(-94.7%)
Jun 2019
-
$5.52 M(+69.9%)
-$3.72 M(-60.6%)
Mar 2019
-$9.44 M(+2866.4%)
$3.25 M(-126.3%)
-$9.44 M(-26.1%)
Dec 2018
-
-$12.33 M(+7917.4%)
-$12.78 M(+2220.1%)
Sep 2018
-
-$153.80 K(-25.1%)
-$550.80 K(+19.4%)
Jun 2018
-
-$205.30 K(+130.2%)
-$461.30 K(+44.9%)
Mar 2018
-$318.30 K(-106.2%)
-$89.20 K(-13.0%)
-$318.30 K(+38.9%)
Dec 2017
-
-$102.50 K(+59.4%)
-$229.10 K(-173.6%)
Sep 2017
-
-$64.30 K(+3.2%)
$311.20 K(-85.9%)
Jun 2017
-
-$62.30 K(-114.2%)
$2.21 M(-14.3%)
Mar 2017
$5.17 M
-
-
DateAnnualQuarterlyTTM
Nov 2016
-
$437.80 K(-76.1%)
$2.57 M(-47.6%)
Aug 2016
-
$1.83 M(+362.9%)
$4.91 M(-14.7%)
May 2016
-
$395.60 K(-540.5%)
$5.76 M(-5.2%)
Feb 2016
$6.07 M(-0.4%)
-$89.80 K(-103.2%)
$6.07 M(-17.3%)
Nov 2015
-
$2.78 M(+3.8%)
$7.35 M(-8.8%)
Aug 2015
-
$2.68 M(+276.5%)
$8.05 M(+18.2%)
May 2015
-
$710.60 K(-40.0%)
$6.81 M(+11.8%)
Feb 2015
$6.10 M(-134.9%)
$1.18 M(-66.0%)
$6.10 M(-140.2%)
Nov 2014
-
$3.48 M(+142.7%)
-$15.16 M(-9.8%)
Aug 2014
-
$1.44 M(<-9900.0%)
-$16.81 M(-6.8%)
May 2014
-
-$7600.00(-100.0%)
-$18.04 M(+3.2%)
Feb 2014
-$17.48 M(-1042.3%)
-$20.07 M(-1196.8%)
-$17.48 M(-745.4%)
Nov 2013
-
$1.83 M(+778.2%)
$2.71 M(+142.7%)
Aug 2013
-
$208.40 K(-62.6%)
$1.12 M(-48.5%)
May 2013
-
$556.90 K(+395.5%)
$2.17 M(+16.9%)
Feb 2013
$1.85 M(-161.6%)
$112.40 K(-52.8%)
$1.85 M(-21.3%)
Nov 2012
-
$238.10 K(-81.1%)
$2.36 M(-193.0%)
Aug 2012
-
$1.26 M(+419.2%)
-$2.53 M(-22.7%)
May 2012
-
$242.90 K(-60.5%)
-$3.28 M(+8.9%)
Feb 2012
-$3.01 M(+16.9%)
$614.60 K(-113.2%)
-$3.01 M(-42.2%)
Nov 2011
-
-$4.65 M(-998.9%)
-$5.21 M(+239.2%)
Aug 2011
-
$517.70 K(+1.1%)
-$1.54 M(-25.6%)
May 2011
-
$511.90 K(-132.3%)
-$2.06 M(-19.9%)
Feb 2011
-$2.57 M(-235.1%)
-$1.58 M(+61.4%)
-$2.57 M(+431.2%)
Nov 2010
-
-$981.20 K(>+9900.0%)
-$484.50 K(-148.6%)
Aug 2010
-
-$9400.00(-1275.0%)
$996.90 K(+0.0%)
May 2010
-
$800.00(-99.8%)
$996.50 K(-47.7%)
Feb 2010
$1.90 M
$505.30 K(+1.0%)
$1.90 M(+36.1%)
Nov 2009
-
$500.20 K(-5204.1%)
$1.40 M(+55.6%)
Aug 2009
-
-$9800.00(-101.1%)
$899.20 K(-1.1%)
May 2009
-
$909.00 K
$909.00 K

FAQ

  • What is Grace Therapeutics annual cash flow from investing activities?
  • What is the all time high annual CFI for Grace Therapeutics?
  • What is Grace Therapeutics annual CFI year-on-year change?
  • What is Grace Therapeutics quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Grace Therapeutics?
  • What is Grace Therapeutics quarterly CFI year-on-year change?
  • What is Grace Therapeutics TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Grace Therapeutics?
  • What is Grace Therapeutics TTM CFI year-on-year change?

What is Grace Therapeutics annual cash flow from investing activities?

The current annual CFI of GRCE is $104.00 K

What is the all time high annual CFI for Grace Therapeutics?

Grace Therapeutics all-time high annual cash flow from investing activities is $13.15 M

What is Grace Therapeutics annual CFI year-on-year change?

Over the past year, GRCE annual cash flow from investing activities has changed by -$13.05 M (-99.21%)

What is Grace Therapeutics quarterly cash flow from investing activities?

The current quarterly CFI of GRCE is $0.00

What is the all time high quarterly CFI for Grace Therapeutics?

Grace Therapeutics all-time high quarterly cash flow from investing activities is $13.26 M

What is Grace Therapeutics quarterly CFI year-on-year change?

Over the past year, GRCE quarterly cash flow from investing activities has changed by +$6.55 M (+100.00%)

What is Grace Therapeutics TTM cash flow from investing activities?

The current TTM CFI of GRCE is -$21.00 K

What is the all time high TTM CFI for Grace Therapeutics?

Grace Therapeutics all-time high TTM cash flow from investing activities is $16.66 M

What is Grace Therapeutics TTM CFI year-on-year change?

Over the past year, GRCE TTM cash flow from investing activities has changed by +$1.43 M (+98.55%)